Author:
Budnevskiy A V,Burlachuk V T,Olisheva LA
Abstract
This article reviews the significance of distal airways inflammation in asthma, current methods of investigations
and therapeutic approaches to control inflammation at the level of small bronchi.
It is demonstrated that inflammation in most asthma patients involves all airways including the small bronchi.
The new drugs targeting distal airways, including extrafine formulations of inhaled steroids and P2-agonists
(beclomethazone/formoterol (Fostair), can successfully treat pathologic process in small bronchi of asthma
patients.
Reference52 articles.
1. Beasley R. The Global Burden of Asthma Report, Global Initiative for Asthma (GINA). Available from <http://www>.ginasthma.org <http://ginasthma.org>. 2004.
2. MasoliM., FabianD., Holt S., Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004, v. 59, p. 469-478.
3. Bousquet J., Jeffery P.K., Busse W.W. et al. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am. J. Respir. Crit. Care Med., 2000, v. 161, No. 5. p. 1720-1745.
4. Cohn L., Elias J.A., Chupp G.L. Asthma: mechanisms of disease persistence and progression. Ann. Rev. Immunol. 2004, v. 22. p. 789-815.
5. GINA Report, Global Strategy for Asthma Management and Prevention. Updated December. 2009.